首页> 外文期刊>Journal of Cancer >A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio
【24h】

A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio

机译:合并检查淋巴结,肿瘤位置和阳性淋巴结比率的可切除胰腺导管腺癌的精确分期模型

获取原文
           

摘要

Background: Nodal status and tumor site are prognostic factors for resectable pancreatic ductal adenocarcinoma (PDAC). Parameters for nodal status are diverse, and the number of examined lymph nodes (eNs) needed for good prognosis are uncertain. We try to modify staging system of resectable PDAC with parameters mentioned above by recursive partitioning analysis. Methods: Patients from the Surveillance, Epidemiology, and End Results (SEER) database were divided into training cohort and internal validation cohort, randomly. PDAC patients from Sun Yat-sen University Cancer Center were regarded as external validation cohort. The training cohort was used to refine staging model by recursive partitioning analysis, while the internal validation cohort and the external validation cohort were applied to assess discriminatory capacity of staging model. For parameters included in the modified model, their effects were studied. Results: The number of eNs, tumor site and tumor size were risk factors for positive nodal status. Lymph nodes ratio (LNR), tumor site, eNs and T stages of 8th the American Joint Committee on Cancer (AJCC) were selected to develop a refined model, dividing patients into 5 groups of different outcomes, preceding 8th AJCC classification. Besides, we found that (1) for small PDAC (diameter 1cm), lymph node metastasis was rarely found; (2) enough eNs were needed to ensure better prognosis of node-negative patients; (3) tumors in the head of pancreas were prone to lymph nodes metastasis; (4) for node-positive patients, LNR was a better nodal parameter compared to positive lymph nodes (pNs). Conclusion: Our improved staging system helps to illuminate the interactions among tumor site, size and eNs.
机译:背景:淋巴结状态和肿瘤部位是可切除的胰腺导管腺癌(PDAC)的预后因素。淋巴结状态的参数各不相同,并且良好的预后需要检查的淋巴结(eNs)数量不确定。我们尝试通过递归分区分析,用上述参数修改可切除PDAC的分级系统。方法:将来自监测,流行病学和最终结果(SEER)数据库的患者随机分为训练组和内部验证组。中山大学癌症中心的PDAC患者被视为外部验证队列。训练队列用于通过递归分区分析来完善分级模型,而内部验证队列和外部验证队列则用于评估分级模型的区分能力。对于修改后的模型中包含的参数,研究了它们的影响。结果:eNs数量,肿瘤部位和肿瘤大小是淋巴结阳性的危险因素。选择第8届美国癌症联合委员会(AJCC)的淋巴结比率(LNR),肿瘤部位,eNs和T期来建立精确模型,在第8届AJCC分类之前将患者分为5组不同的结局。此外,我们发现(1)对于较小的PDAC(直径<1cm),很少发现淋巴结转移; (2)需要足够的eN来确保淋巴结阴性患者的更好预后; (3)胰头肿瘤易发生淋巴结转移; (4)对于淋巴结阳性患者,与淋巴结阳性(pNs)相比,LNR是更好的淋巴结参数。结论:我们改进的分期系统有助于阐明肿瘤部位,大小和eNs之间的相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号